Form PT

Form PTO 449 (Modified)

ΑĴ

LIST OF PATENTS AND PUBLICATIONS FOR ADIA DELICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

ATTORNEY DOCKET NO. 31505.0002

SERIAL NO. 10/037,516

APPLICANT Ashkan Imanzahrai

FILING DATE 01/04/2002

GROUP 1614

REFERENCE DE	CICNATI	ON					U.S.	PATE	NT DOCUMEN	<u>TS</u>			
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
(M)	AA 3 0 8 0 2 8 7		7	03/05/63	Lewenstein	167	65	08/05/57					
	AB	4	0		7	6	1	4	04/12/77	Wild	424	232	12/05/75
	AC	4	5	8	5	8	6	6	04/29/86	Fozard et al.	546	129	12/13/84
	AD	4	7	5	8	4	3	3	07/19/88	Johnson et al.	424	195.1	06/26/85
	AE	5	0	5	3-	3	9	6	10/01/91	Blass	514	45	08/01/90
	AF	5	2	7	3 .	7	5	9	12/28/93	Simmons	424	465	09/17/92
	AG	5	5	3	8 -	9	5	9	07/23/96	Mauskop	514	165	01/26/95
	AH	5	9	7	2	9	,	6	10/26/99	Armellino et al.	514	165	02/10/98
11 -	1 (1)				<u></u>	<u> </u>						1	1

								FO	REIGN PATE	NT DO	CUMENTS			<del></del>	г	
	DOCUMENT NUMBER														TRANSLATION	
									DATE	COUNTRY	CLA	CLASS	SUBCLASS	YES	NO	
	AL															
·	AM												_			<u> </u>
	AN														<u> </u>	<u></u>

			OTHER ART (Including Author, Title, Date, Pertinent Pages, Ftc.)
U	M	AO	Goadsby, "Mechanisms and management of headache," JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON, Vol. 33, No. 3,  May/June 1999, pp 228-234
			Lipton et al., "Migraine in the United States: A review of epidemiology and health care use," NEUROLOGY 43 (Suppl 3) June 1993, pp S6-S10
		AP	week frequency and duration." NEUROLOGY 44 (Suppl 4) June 1994.
ļ.		AQ	Stewart et al., "Migraine heterogeneity Disability pain intensity, and attack frequency and duration," NEUROLOGY 44 (Suppl 4) June 1994,  pp S24 - S39
TECH C		AR	Rasmussen et al., "Impact of headache on sickness absence and utilisation of medical services: a Danish population study, " JOURNAL OF EPIDEMIOLOGY  AND COMMUNITY HEALTH 1992; 46, pp 443-446
ECH CENTER 1600/2900	TIPE CONTRACTOR	AS	Lipton et al., "Undiagnosed Migraine Headaches A Comparison of Sympton-Based and Reported Physician Diagnosis," ARCH INTERN MED-Vol 152, June 1992, pp 1273 - 1278
0/2900	U U	1	

Page	2	οf	

			Page 2 of 3
			Edmeads et al., "mpact of Migraine and Tension-Type Headache on Life-Style, Consulting Behavior, and Medication Use: A Canadian Population Survey,"
1 . ^	MA AT		
W	NO		LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES, 1993; 20, pp 131-137
			Rasmussen et al., "Epidemiology of Migraine," THE HEADACHES, SECOND EDITION, pp 227 - 234
1 1		ΑÜ	
1 1			
			<u> </u>
			Olesen, "A review of current drugs for migraine," JOURNAL OF NEUROLOGY (1991) 238, pp S23-S27
		ΑV	
<b> </b>			
			Solomon, "Therapeutic Advances in Migraine," J CLIN PHARMACOL 1993; 33, pp 200-209
		AW	
ļ:			
<b>i</b>			
			Laska et al., "Caffeine as an Analgesic Adjuvant," THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, April 6, 1984, Vol 251, No. 13,
		AX	pp 1711 - 1718
<b></b>	1 1		
			Schmidt et al., "Effect of Caffeine on Intestinal Absorption of Ergotamine in Man," EUROP. J. CLIN. PHARMACOL. 7 (1974), pp 213-216
1		AY	
	1		
<b> </b>	1 1		
	1 1		Stang et al., "Migraine Patterns of healthcare use," NEUROLOGY 1994; 44 (Suppl 4), pp S47-S55
	] [	AZ	
lf			
<b>}</b>	+		
			Stewart et al., "Prevalence of Migraine Headache in the United States Relation to Age, Income, Race, and Other Sociodemographic Factors," JAMA, January 1,
		BA	1992-Vol 267, No. 1, pp 64-69
	- 1 1		
1			
	1		Deleu et al., "Symptomatic and Prophylactic Treatment of Migraine: A Critical Reappraisal," CLINICAL NEUROPHARMACOLOGY, Vol 21, No. 5,
l.	1	BB	pp 267-269
	11		
			Clissold, "Paracetamol and Phenacetin," DRUGS 32 (Suppl. 4) (1986), pp 46-59
		BC	
	11		
	1 1		
I		_	Hughes et al., "Review Articles Effects of Pseudoephedrine in Man," JOURNAL OF CLINICAL AND HOSPITAL PHARMACY (1983) 8, pp 315-321
		BD	
1			
<del> </del>	<b>├</b> ─}		
<u> </u>			Munari et al, "Pharmacologic Evaluation of Cardiovascular Reflex Responses In Migraine Patients: Lack of Central Sympathetic Modulation?", FUNCTIONAL
/		BE	NEUROLOGY 4(4) 1989, pp 375-378
	[	ı	1120102003 T(3) 1707, pp 313-310
<b>P</b>		0	
6	<b>⊋</b> Æ	ñ	Diamond, "Head Pain Diagnosis and Management," CLINICAL SYMPOSIA, Ciby-Geigy Corporation, Volume 46, Number 3, 1994, pp 1-34
	⊋ ⊁	BF	
	, <u>}</u>	╣┆	
	╼╌Щ	╩┦	
阿公	⊰ / ₹		Lipton, et al., "Over The Counter Medication and the Treatment of Migraine," HEADACHE 1994; 34, pp 547-548
EGH CENTER 1600/290	§/ <b>f</b> f	a [	
	~ #	┪╏	
<b>2</b>			

/-

TPE		Page 3 of 3
7 10 7 (10)1922		Migliardi et al., "Caffeine as an analgesic adjuvant in tension headache," CLINICAL PHARMACOLOGY & THERAPEUTICS, Volume 56, Number 5, pp 576-586
TRADEMARY		Sawynok, "Pharmacological Rationale for the Clinical Use of Caffeine," DRUGS 49 (1) 1995, pp 37-50
	Bi	Celentano et al., "Medication Use and Disability Among Migraineurs: A National Probability Sample Survey," HEADACHE 1992; 32, pp 223-228
	BJ	Celentario et al., medicario, occurrente de la companya del companya de la companya de la companya del companya de la companya
	вк	Lipton et al., "Medical Consultation for Migraine: Results of the AASH-Gallup Survey," and Lipton et al., "Gastrointestinal Symptoms in Migraine: Results from the AASH-Gallup Survey," ADDITIONAL POSTERS PRESENTED AT THE ANNUAL MEETING OF AASH, JUNE 23-25, BOSTON,
		MASSACHUSETTS, p 563
	BL	Lipton et al., "Headache 287P Medical Consultation for Migraine," NEUROLOGY 44 (Suppl. 2) April 1994
	ВМ	"Pseudoephedrine," CLINICAL PHARMACOLOGY ON PHYSICIANS' ONLINE, pp 1-2
	BN	"Caffeine," CLINICAL PHARMACOLOGY ON PHYSICIANS' ONLINE, pp 1-2
	ВО	"Acetaminophen," CLINICAL PHARMACOLOGY ON PHYSICIANS' ONLINE, pp 1-3
	ВР	"Acetaminophen; Pseudoephedrine," CLINICAL PHARMACOLOGY ON PHYSICIANS' ONLINE, pp 1-3
	BQ	"Acetaminophen; Caffeine," CLINICAL PHARMACOLOGY ON PHYSICIANS' ONLINE, pp 1-2
	BR	"Caffeine," CLINICAL PHARMACOLOGY ON PHYSICIANS' ONLINE,, pp 1-3
		1000
FXAMINE		reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
EXAMINER	: Initial if of this for	m with next communication to applicant.

BFLODOCS:401023\_1 (8LFJ01)

(Information Disclosure Statement-Section 9 PTO-1449 (Modified) [6-1]))